PT  - JOURNAL ARTICLE
AU  - Li, Chen
AU  - Jay, Nicolas De
AU  - Sharma, Supriya
AU  - Catalano, Katrina A.
AU  - Holzinger, Emily R.
AU  - Sridharan, Venkatesh
AU  - Wang, Zhaoqing
AU  - Zhao, Lei
AU  - Szustakowski, Joseph D.
AU  - Chang, Ching-Pin
AU  - Maranville, Joseph C.
AU  - Kvikstad, Erika M.
TI  - Proteome-wide Mendelian randomization identifies candidate causal proteins for cardiovascular diseases
AID  - 10.1101/2023.10.16.23297103
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.10.16.23297103
4099  - http://medrxiv.org/content/early/2023/10/17/2023.10.16.23297103.short
4100  - http://medrxiv.org/content/early/2023/10/17/2023.10.16.23297103.full
AB  - Background Cardiovascular diseases (CVD) remain the leading cause of death worldwide, while a lack of clarity on underlying mechanisms has hindered development of novel therapies. Integration of human genetics and proteomics across different ancestries can provide novel, affordable, and systematic approach for target identification and prioritization.Methods Mendelian randomization approach was applied to unravel causal associations between 2,940 circulating proteins and 21 CVD. Genome-wide summary statistics from the largest genetic mapping of human plasma proteome and meta-analyses on CVD across FinnGen, UK Biobank and Biobank Japan were used. Forward and reverse causation were studied to distinguish respective targets and biomarkers. Genetic instruments for Europeans and East Asians were derived separately and applied to the cardiovascular outcomes in cohorts from corresponding ancestries. We further prioritized drug targets by integrating biological, clinical and population study evidence from cross-database annotations and literature review. Single-cell enrichment analysis and phenome-wide causality scan were performed to further understand target mechanism of action.Results We found 221 novel candidate causal proteins that impacted risk of one or more CVD through forward MR, and 16 biomarkers whose expression levels were affected by CVD through reverse MR (Bonferroni-adjusted P-value <= 0.05). Forward and reverse MR found largely non-overlapping proteins among CVD (only 2 overlapped: LGALS4 and MMP12), suggesting distinct proteomic causes and consequences of CVD. Many of the candidate causal proteins (73.4%) identified are supported by strong literature evidence for a role in immune response and atherosclerotic lesion formation, angiogenesis and vascular remodeling, myogenesis and cardiac progenitor cell differentiation, and energy metabolism. Single cell integration further prioritized ADAM23 for cardiomegaly, PAM for stable angina pectoris and ventricular arrythmia and LPL for peripheral artery disease, whose transcript expression were enriched in cardiomyocytes. Three protein functional groups were highlighted in the phenome-wide scan for their specific enrichment for CVD, including blood coagulation and fibrinolysis, angiogenesis and vascular remodeling, and cell proliferation and myogenesis.Conclusions Our study identified potential therapeutic targets for CVD and distinguished them from biomarkers due to reverse causation. This study provides human genetics-based evidence of novel candidate genes, a foundational step towards full-scale causal human biology-based drug discovery for CVD.Competing Interest StatementAll authors are employees and/or stockholders of Bristol-Myers Squibb.Funding StatementThis study was funded by the Bristol-Myers Squibb.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The details of the IRB/oversight body that provided approval or exemption for the research described are given below: All participants provided informed consent. This research has been conducted using the UK Biobank Resource under approved application numbers 26041 and 65851. The included GWAS all received informed consent from study participants and have been approved by pertinent local institutional review board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.